← Back to Screener
HUTCHMED (China) Limited American Depositary Shares (HCM)
Price$15.36
Favorite Metrics
Price vs S&P 500 (26W)-7.25%
Price vs S&P 500 (4W)2.47%
Market Capitalization$20.62B
P/E Ratio (Annual)5.76x
All Metrics
P/CF (Annual)4930.73x
Book Value / Share (Quarterly)$1.42
Revenue Growth (3Y)8.76%
Cash Flow / Share (Quarterly)$-0.10
Price vs S&P 500 (YTD)16.67%
Gross Margin (TTM)38.68%
Net Profit Margin (TTM)83.30%
EPS (TTM)$0.52
10-Day Avg Trading Volume5.99M
EPS Excl Extra (TTM)$0.52
Revenue Growth (5Y)19.20%
EPS (Annual)$0.52
ROI (Annual)34.20%
Gross Margin (Annual)38.68%
Net Profit Margin (5Y Avg)-7.59%
Cash / Share (Quarterly)$1.57
P/E Basic Excl Extra (TTM)5.76x
Revenue Growth QoQ (YoY)-16.54%
P/E Normalized (Annual)5.76x
ROA (Last FY)26.06%
Revenue Growth TTM (YoY)-12.96%
EBITD / Share (TTM)$0.04
ROE (5Y Avg)-20.94%
Operating Margin (TTM)-7.14%
Cash Flow / Share (Annual)$-0.10
P/B Ratio2.13x
P/B Ratio (Quarterly)1.84x
Net Income / Employee (Annual)$0
Net Interest Coverage (TTM)13.00x
ROA (TTM)25.89%
EPS Growth QoQ (YoY)-83.94%
EPS Incl Extra (Annual)$0.52
Current Ratio (Annual)4.96x
Quick Ratio (Quarterly)4.81x
3-Month Avg Trading Volume4.71M
P/E Incl Extra (TTM)5.76x
Revenue / Employee (TTM)$0
P/S Ratio (Annual)4.80x
Asset Turnover (Annual)0.31x
52-Week High$30.75
Operating Margin (5Y Avg)-33.42%
EPS Excl Extra (Annual)$0.52
CapEx CAGR (5Y)4.28%
26-Week Price Return-3.26%
Quick Ratio (Annual)4.81x
13-Week Price Return8.19%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)4.96x
Enterprise Value$2,658.711
Revenue / Share Growth (5Y)13.98%
Asset Turnover (TTM)0.31x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)6.73x
Pretax Margin (Annual)95.05%
Cash / Share (Annual)$1.57
3-Month Return Std Dev34.77%
Gross Margin (5Y Avg)38.39%
Net Income / Employee (TTM)$0
ROE (Last FY)36.91%
Net Interest Coverage (Annual)3.54x
EPS Basic Excl Extra (Annual)$0.52
P/FCF (TTM)784.31x
Receivables Turnover (TTM)3.86x
Total Debt / Equity (Quarterly)0.08x
EPS Incl Extra (TTM)$0.52
Receivables Turnover (Annual)4.73x
ROI (TTM)34.38%
P/S Ratio (TTM)4.80x
Pretax Margin (5Y Avg)-2.66%
Revenue / Share (Annual)$0.63
Forward P/E51.21x
P/E Ratio (TTM)5.76x
EPS Growth TTM (YoY)1109.24%
Year-to-Date Return17.85%
5-Day Price Return2.97%
EPS Normalized (Annual)$0.52
ROA (5Y Avg)-12.66%
Net Profit Margin (Annual)83.30%
Month-to-Date Return7.14%
EBITD / Share (Annual)$-0.02
Operating Margin (Annual)-7.16%
LT Debt / Equity (Annual)0.06x
ROI (5Y Avg)-19.80%
P/E Excl Extra (TTM)5.76x
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$0.52
P/B Ratio (Annual)1.84x
Inventory Turnover (TTM)7.09x
Pretax Margin (TTM)95.05%
Book Value / Share (Annual)$1.42
Price vs S&P 500 (13W)7.50%
Beta1.12x
P/FCF (Annual)14.10x
Revenue / Share (TTM)$0.63
ROE (TTM)37.04%
52-Week Low$19.95
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HCMHUTCHMED (China) Limited American Depositary Shares | 4.80x | -12.96% | 38.68% | — | $15.36 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
HUTCHMED is a biopharmaceutical company developing targeted therapies and immunotherapies for cancer and immunological diseases. The company maintains a robust pipeline of cancer drug candidates in clinical development while leveraging significant commercial infrastructure in China. Operating across Oncology/Immunology and Other Ventures segments, HUTCHMED combines early-stage innovation with established regional market presence.